Results 151 to 160 of about 194,967 (316)
ESC Heart Failure, Volume 12, Issue 2, Page 1176-1182, April 2025.Abstract Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is an increasinglyrecognized cause of heart failure with preserved ejection fraction (HFpEF), which may be diagnosed non‐invasively using 99mTc 3,3‐diphosphono‐1,2‐propanodicarboxylic acid (DPD) scintigraphy‐based diagnostic criteria.
L. Healy +15 more
wiley +1 more source
Interventional therapies for chronic heart failure: An overview of recent developments
ESC Heart Failure, Volume 12, Issue 2, Page 1081-1094, April 2025.Abstract Heart failure (HF), the final manifestation of most cardiovascular diseases, has become a major global health concern, affecting millions of individuals. Despite basic drug treatments, patients present with high morbidity and mortality rates. However, recent advancements in interventional therapy have shown promising results in improving the ...
Bingchen Guo +7 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1237-1245, April 2025.Abstract Aims Immune checkpoint inhibitors (ICI) are the cornerstone of modern oncology; however, side effects such as ICI‐related myocarditis (irM) can be fatal. Recently, Bonaca proposed criteria for irM; however, it is unknown if they correlate well with cardiovascular (CV) ICI‐related adverse events.
Lorenzo Braghieri +12 more
wiley +1 more source
Considerations for drug trials in hypertrophic cardiomyopathy
ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant +17 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1295-1303, April 2025.Abstract Background Obesity is a known risk factor for cardiovascular disease (CVD), yet an ‘obesity paradox’ has been observed in various CVD contexts. The impact of obesity on heart failure (HF) patients treated with a wearable cardioverter‐defibrillator (WCD) remains underexplored.
Mohammad Abumayyaleh +18 more
wiley +1 more source
Ictal ECG changes in temporal lobe epilepsy.
, 1995 Changes in cardiac rhythm may occur during epileptic seizures and this has been suggested as a possible mechanism for sudden unexpected death amongst patients with chronic epilepsy (SUDEP).
Sander, JW, Roche, J, Li, LM
core
ESC Heart Failure, Volume 12, Issue 2, Page 1316-1325, April 2025.Abstract Objective This study aimed to evaluate the utility of left atrial volume and function in uraemic patients using four‐dimensional automatic left atrial quantification (4D auto LAQ) technology. Methods Thirty‐four undialysed uraemic patients (U‐ND group), 60 dialysed uraemic patients (U‐D group), and 32 healthy volunteers (N group) were enrolled
Bing Li, Meihua Chen, Xuning Huang
wiley +1 more source
Noninvasive optogenetic induction of cardiac arrhythmias alters systemic hemodynamics in mice. [PDF]
Sci AdvAmaral MM +17 more
europepmc +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1326-1335, April 2025.Abstract Aims Amyloid cardiomyopathy is caused by the deposition of light chain (AL) or transthyretin amyloid (ATTR) fibrils, that leads to a restrictive cardiomyopathy, often resulting in heart failure (HF) with preserved or reduced ejection fraction.
Robin Willixhofer +25 more
wiley +1 more source